Trang 1 từ 29 các kết quả
FIELD OF THE INVENTION
The present invention relates to certain 3H-imidazo[4,5-b]pyridin-5-ol derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the GPR81 receptor. Also provided by the present
TECHNICAL FIELD
The present invention relates to a nitrogen-containing bicyclic compound or a pharmacologically acceptable salt thereof and a pharmaceutical composition comprising it as active ingredient.
More specifically, the present invention relates to (1) a compound of formula (I)
##STR00002##
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 13, 2017, is named 191Sequence_ST25.txt and is 4,393 bytes in size.
FIELD
The
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein
R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl,
R.sub.b
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
FIELD OF INVENTION
The present invention is directed to modulators of the TGR5 receptor useful in the treatment of TGR5 mediated diseases or disorders. Specifically, the invention is concerned with compounds and compositions thereof, which activate the TGR5 receptor, methods of treating diseases or
FIELD OF THE INVENTION
The present invention relates to a composition comprising one or more oxalate degrading enzymes for delivering the enzymes in active form to the stomach, where the one or more oxalate degrading enzymes exert their effect. Thus, the present invention provides means for reducing
FIELD OF THE INVENTION
The present invention in general relates to an intestinal nutrient absorption barrier and in particular to a disintegratable or segmentable barrier.
BACKGROUND OF THE INVENTION
Obesity has reached pandemic proportion in the United States with 55% of adults and 25% of children
The present invention relates to heterocyclic compounds, to pharmaceutical compositions containing them, and to methods of treating conditions mediated by the Peroxisome Proliferator-Activated Receptor (PPAR) activity by employing such compounds.
Accordingly, the present invention provides compounds
The present invention provides compounds of the formula
##STR00002## wherein R.sub.1 and R.sub.2 are independently hydrogen, halogen, hydroxy, optionally substituted alkyl, alkoxy, alkylthio, aralkyl or heteroaralkyl; or R.sub.1 and R.sub.2 combined together with the carbon atoms to which they are
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the 35 U.S.C. .sctn.371 national stage of PCT application PCT/JP2005/007354, filed Apr. 11, 2005, which claims priority to Japanese patent application No. 116725/2004, filed Apr. 12, 2004. The contents of these applications are incorporated
FIELD OF THE INVENTION
The invention relates to synthetic peptide amides incorporating D-amino acids in the peptide chain and more particularly to such synthetic peptide amides that are kappa opioid receptor agonists, and methods for their use as prophylactic and therapeutic agents for the
FIELD OF THE INVENTION
The invention relates to synthetic peptide amides incorporating D-amino acids in the peptide chain and more particularly to such synthetic peptide amides that are kappa opioid receptor agonists, and methods for their use as prophylactic and therapeutic agents for the
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a 35 U.S.C. 371 national application of PCT/DK96/00069 filed Feb. 12, 1996, and claims priority under 35 U.S.C. 119 of Danish application 0176/95 filed Feb. 17, 1995, the contents of which are fully incorporated herein by reference.
FIELD